RxDoctor Payments Data

Marvi Miranda, MD

General Practice · Delhi, CANPI 1609265602

Payments from drug & device makers

$1,391in general payments, 2019–2025

Across 81 payments — averaging $17.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$300
  • Merck$133
  • Sanofi-aventis U.S. LLC$125
  • Johnson & Johnson$116
  • Teva Pharmaceuticals USA, Inc.$105
  • Pfizer$102
  • plus $510 from 13 others

What the payments were for

  • Food & beverage$1,391100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,391 in reported general payments places this provider in the 85th percentile of 12,963 general practice providers in California.

See all general practice providers in California

Medicare billing

Part B allowed, 2024
$163,349
Medicare patients
248
Services billed
2,608

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide121$126,708
TrulicityDulaglutide92$89,556
JardianceEmpagliflozin76$73,694
EliquisApixaban52$52,891
XareltoRivaroxaban32$33,923
MounjaroTirzepatide35$32,815
JanuviaSitagliptin Phosphate26$27,171
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$19,221
TradjentaLinagliptin12$16,250
RybelsusSemaglutide16$15,667
Spiriva RespimatTiotropium Bromide13$12,191
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog31$11,901
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen319$9,692
Atorvastatin Calcium644$8,619
Repatha SureclickEvolocumab14$7,820

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$72$142,375137 claims
Lilly USA, LLCTrulicity, Mounjaro$99$122,371127 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Combivent Respimat$11$109,472116 claims
PfizerEliquis$102$52,89152 claims
Johnson & JohnsonXarelto$116$33,92332 claims
MerckJanuvia$133$27,17126 claims
GSKTrelegy Ellipta, Breo Ellipta$300$23,12439 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 12,963 general practice providers in California.

Other general practice in Delhi

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →